With obesity affecting more than one billion people globally and the market for obesity therapeutics projected to grow dramatically over the next decade, the stakes for sponsors have never been higher. Driven by breakthrough therapies, rapid market expansion, and intense competition among developers racing to define the next generation of metabolic medicine, obesity has become one of the most important areas of pharmaceutical innovation.

But as the science matures, the industry’s focus is beginning to shift.

The question is no longer whether a therapy can help patients lose weight. Increasingly, sponsors, regulators, clinicians, and investors want to know whether those therapies can meaningfully alter the trajectory of cardiovascular disease, chronic kidney disease (CKD), heart failure, and other complications along the metabolic continuum that drive long-term morbidity, mortality, and healthcare costs. As a result, competitive differentiation is shifting from weight-loss efficacy alone to the ability to demonstrate durable cardiovascular, renal, and metabolic outcomes.

That transition represents one of the most important developments in cardiometabolic drug development today.

Obesity Has Opened the Door to a Bigger Conversation

The commercial success of GLP-1 receptor agonists transformed obesity research from a niche therapeutic area into one of the largest growth opportunities in healthcare. Yet obesity itself may only be part of the story.

Cardiovascular disease remains responsible for approximately two-thirds of obesity-related excess mortality. Furthermore, clinical evidence indicates that over 80% of individuals living with type 2 diabetes or heart failure with preserved ejection fraction (HFpEF) present with overlapping overweight or obesity conditions.

For sponsors, the result is a higher evidentiary bar. Demonstrating weight loss may earn attention, but increasingly it is cardiovascular, renal, and long-term outcomes data that drive differentiation.

“Obesity has rightly become part of the cardiovascular conversation, but it should not become a new silo,” says Prof. Rick Grobbee, MD, Chief Scientific Officer at P95 Julius Clinical. “Obesity, diabetes, CKD, hypertension, dyslipidaemia, and heart failure are increasingly understood as overlapping expressions of cardiometabolic risk.”

That perspective is increasingly reflected in development programs that extend beyond weight reduction and evaluate cardiovascular outcomes, renal outcomes, heart-failure endpoints, symptoms, and physical functioning.

Weight Loss Alone Is No Longer Enough

Historically, metabolic drug development often focused on surrogate endpoints such as HbA1c reduction or body weight percentage.

Today, expectations are expanding. Recent cardiometabolic outcomes trials have demonstrated clinically meaningful reductions in major adverse cardiovascular events and renal outcomes, raising expectations for the evidence packages that future therapies will need to deliver. As a result, endpoints measuring hospitalizations, functional capacity, quality of life, and disease progression are becoming baseline expectations rather than secondary highlights.

Prof. Grobbee believes this evolution is both necessary and inevitable. “Weight loss is clinically important, but it is not the final outcome,” he says. “The most valuable evidence will tell clinicians not only whether a therapy works, but where it fits among several effective options and how its benefits can be sustained.”

For sponsors operating in increasingly crowded therapeutic categories, demonstrating those broader benefits may ultimately prove more important than incremental differences in weight reduction alone.

The Most Important Patients Are Often Missing From Trials

As cardiometabolic disease becomes better understood, another challenge is becoming increasingly apparent: many clinical trials still fail to reflect the complexity of patients seen in practice.

Historically, clinical development programs have relied on increasingly narrow inclusion and exclusion criteria to maximize the likelihood of generating a clear answer. While that approach can simplify study execution, it can also create trial populations that look very different from the patients physicians ultimately treat.

“Sometimes patients in trials are designed on a drawing board that are really hard to find in real life,” says Prof. Dr. Grobbee. “The bottom line is that the patient becomes a very rare species.”

According to Prof. Grobbee, the industry’s pursuit of narrowly defined patient populations can come at the expense of real-world relevance. A “clean” obesity population may be attractive from a study design perspective, but it often fails to reflect the patients clinicians encounter every day.

The challenge is particularly acute in cardiometabolic disease, where multimorbidity is increasingly the norm rather than the exception. Patients with obesity frequently have overlapping diabetes, hypertension, chronic kidney disease, dyslipidaemia, heart failure, or multiple combinations of these conditions. Recent clinical consensus statements characterize these diseases as interconnected manifestations of cardiometabolic risk rather than isolated disorders.

For sponsors, the implication is clear: future development programs will need to demonstrate effectiveness across more representative patient populations while generating evidence that reflects the realities of multimorbidity. The goal is no longer simply proving efficacy in an ideal patient. It is demonstrating meaningful benefit in the patients most likely to be treated in routine practice. That shift will require closer collaboration between sponsors, CROs, investigators, and healthcare systems to identify, recruit, and retain patient populations that better reflect real-world clinical practice.

 Why CKD May Be Cardiometabolic Development’s Biggest Unmet Opportunity

While obesity has captured much of the industry’s attention, Prof.  Grobbee believes CKD remains one of the most significant unmet opportunities in cardiometabolic research.

“Cardiovascular disease and CKD form one of the largest remaining gaps between scientific opportunity and clinical outcomes,” he says.

For drug developers, that creates a rare combination of large unmet need, growing clinical attention, and significant opportunity for differentiation. Global estimates indicate that over 850 million people live with kidney disease, yet fewer than 10% of high-risk patients are diagnosed in early, actionable stages. At the same time, patients with impaired kidney function have historically been excluded from many cardiovascular trials, leaving critical evidence gaps in the populations often at highest risk.

For Prof.  Grobbee, that disconnect represents a major opportunity for the next generation of cardiometabolic research.

“CKD substantially increases the risks of heart failure, atherosclerotic events, and death, yet these are precisely the patients who have often been underrepresented in cardiovascular development programs,” he notes.

Future programs, he argues, must move beyond traditional cardiovascular or renal silos and be designed around the reality of multimorbidity. That means broader eligibility criteria, closer collaboration between cardiology and nephrology, and endpoints that more accurately capture both cardiovascular and kidney outcomes.

As sponsors continue to pursue integrated cardiometabolic strategies, CKD is increasingly emerging as both a scientific and commercial opportunity. The companies that can generate meaningful evidence in these complex, high-risk populations may be best positioned to define the next chapter of cardiometabolic innovation.

The Next Phase of Competition Will Be About Outcomes

The cardiometabolic market is entering a new stage of maturity.

The first phase was defined by proving that meaningful weight loss was achievable. The next phase will be defined by demonstrating durable improvements in cardiovascular outcomes, kidney health, symptoms, quality of life, adherence, and long-term risk reduction.

As Prof. Grobbee puts it, “The next generation of cardiovascular outcomes trials must prove not only efficacy, but meaningful and implementable benefit in the patients clinicians actually see.”

For sponsors, CROs, and development partners, that represents both a challenge and an opportunity. The companies that win the next phase of cardiometabolic innovation are unlikely to be those defined solely by weight-loss efficacy. They will be the organizations that can demonstrate meaningful impact across cardiovascular, renal, and metabolic outcomes while generating evidence that reflects the realities of multimorbidity.

As Prof. Grobbee observes, “Patients do not experience these conditions one at a time, and research programmes should not study them as if they do.”

In the emerging cardiometabolic landscape, that may become the defining challenge and the defining opportunity for sponsors alike.